Cardinal Gianfranco Ravasi (image by Getty Images via @daylife)
An international conference entitled: ‘Adult Stem Cells: Science and the Future of Man and Culture‘ is due to begin today in the Vatican, lasting until 11 November. The event, which has been organised by the US Stem for Life Foundation and by the Pontifical Council for Culture, has the aim of supporting research and increasing public awareness of treatment using adult stem cells.
The conference will be attended by 350 scientists, religious figures, politicians, educators and industry representatives.
Primary stem cells are of two kinds: embryonic and adult. When a stem cell
Image by Jessica DeWinter via Flickr
“Stem cells are no longer only the future of aesthetic surgery, they are the present,” said Alessandro Gennai, an associate plastic surgeon at the European Academy of Facial Plastic Surgery (EAFPS). For the past year, Gennai has been using a modified technique used to preserve stem cells in lipofilling procedures. “I have already performed numerous operations, with excellent results and without side-effects,” said the surgeon from Bologna, “therefore I can say that lipofilling is the best solution for someone who wants to eliminate wrinkles before the summer. The procedure lasts 30
Image via Wikipedia
One of the most advanced research centers for the therapeutic applications of epithelial stem cells in the world, the ‘Stefano Ferrari’ regenerative medicine center at the University of Modena and Reggio Emilia, opened its doors with the ambitious goal of becoming the flagship research center in Italy. It was completely financed by the Modena Savings Bank, which invested 13 million euros for its completion and was inaugurated by Welfare Minister Maurizio Sacconi and Emilia-Romagna President Vasco Errani. It includes a new three floor, 30,000 square meter building (half of which is contamination controlled) at
Research on Stem Cell Treatments Abroad
If you have done any research on stem cell treatments abroad, you will undoubtedly read negative articles like this one on CNN from the mainstream media saying these companies are promising cures and are preying on the desperate, that these companies are selling “snake oil” Nothing could […]
MENLO PARK, Calif., August 18, 2009 – Geron Corporation announced that its IND (Investigational New Drug application) for GRNOPC1, a cell therapy for neurologically complete, subacute spinal cord injury, has been placed on clinical hold by the FDA pending the agency’s review of new nonclinical animal study data submitted by the company. A clinical hold is an order that the FDA issues to a sponsor to delay a proposed trial or to suspend an ongoing trial.
Since filing the IND, Geron has been undertaking studies to enable dose escalation of its spinal cord injury product, and has been investigating application